Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
folinic acid + oxaliplatin + irinotecan + bevacizumab
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This regimen is a four-drug combination therapy used primarily for the treatment of metastatic colorectal cancer. It consists of folinic acid (leucovorin), oxaliplatin, irinotecan, and bevacizumab. Folinic acid enhances the efficacy of fluorouracil (not included in this specific query but often part of FOLFOXIRI regimens). Oxaliplatin and irinotecan are cytotoxic chemotherapeutic agents that inhibit DNA synthesis through different mechanisms—oxaliplatin forms DNA crosslinks, while irinotecan inhibits topoisomerase I. Bevacizumab is a recombinant humanized monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), thereby inhibiting angiogenesis required for tumor growth and metastasis[6][8][9]. The combination aims to maximize antitumor activity by attacking cancer cells via multiple pathways and restricting their blood supply.
- Other names
- FOLFOXIRI plus bevacizumab
02
Targets
TOP1 (DNA Topoisomerase I)DHFR (Dihydrofolate reductase)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on folinic acid + oxaliplatin + irinotecan + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on folinic acid + oxaliplatin + irinotecan + bevacizumab.